Evidence map›Paper›PMID 27495088›Full record

ArticleMedicine2016

Complementary traditional Chinese medicine therapy improves survival in patients with metastatic prostate cancer.

Jui-Ming Liu, Po-Hung Lin, Ren-Jun Hsu, Ying-Hsu Chang, Kuan-Chen Cheng, See-Tong Pang, Shun-Ku Lin

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Cannabinoids and Prostate Cancer: A Systematic Review of Animal Studies.International journal of molecular sciences · 2020
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 4 countries.

Jui-Ming LiuDivision of Urology, Department of Surgery, Taoyuan General Hospital, Ministry of Health and Welfare Division of Urology, Department of Surgery, Chang Gung Memorial Hospital Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University Biobank Management Center of the Tri-Service General Hospital, National Defense Medical Center Department of Pathology and Graduate Institute of Pathology and Parasitology, the Tri-Service General Hospital, National Defense Medical Center Graduate Institute of Life Sciences, National Defense Medical Center Graduate Institute of Food Science and Technology, National Taiwan University Institute of Biotechnology, National Taiwan University Department of Medical Research, China Medical University Hospital, China Medical University Department of Chinese Medicine, Taipei City Hospital, Renai Branch, Taipei City, Taiwan.
Po-Hung Lin
Ren-Jun Hsu
Ying-Hsu Chang
Kuan-Chen Cheng
See-Tong Pang
Shun-Ku Lin
Chang Gung Memorial Hospital · TWChina Medical University · CNMemorial Hospital of South Bend · USNational Defense Medical College · JPTaipei City Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

More than 50% of prostate cancer patients have used traditional Chinese medicine (TCM) in Taiwan. However, the long-term clinical efficacy of TCM in prostate cancer patients remains unclear. Here, we investigated the relationship between TCM use and the survival of prostate cancer patients.A retrospective nationwide cohort study of prostate cancer patients was conducted between 1998 and 2003 using the Taiwan National Health Insurance Research Database. Patients were classified as TCM users or nonusers, and monitored from the day of prostate cancer diagnosis to death or end of 2012. The association between death risk and TCM use was determined using Cox proportional-hazards models and Kaplan-Meier curves.Of the 1132 selected prostate cancer patients, 730 (64.5%) and 402 (35.5%) were TCM users and nonusers, respectively. The mean follow-up period was 8.38 years, and 292 (25.8%) deaths were reported. TCM users had a decreased mortality rate (21.9%) compared with nonusers (32.8%). A lower death risk was observed with longer TCM use, especially in patients who used TCM for ≧200 days (adjusted hazard ratio [aHR] 0.61, 95% confidence interval [CI] 0.44-0.84). TCM users with metastatic prostate cancer had a significant lower HR than nonusers (aHR 0.70, 95% CI 0.51-0.95). Chai-Hu-Jia-Long-Gu-Mu-Li-Tang was the most significant TCM formulae for improving survival in metastatic prostate cancer (aHR 0.18, 95% CI 0.04-0.94).The result suggested that complementary TCM therapy might be associated with a reduced risk of death in metastatic prostate cancer patients.

Indexed as

Medicine, Chinese TraditionalAgedAged, 80 and overAge FactorsCohort StudiesComorbidityDatabases, FactualFollow-Up StudiesHumansHypertensionInsurance CoverageLiver CirrhosisLogistic ModelsMaleMiddle AgedProportional Hazards Models

Identifiers

PMID27495088
PMCPMC4979842
OpenAlexW2482832472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.